Frequently asked questions about Gavi's revised co-financing, prepared by the Gavi Secretariat in June 2012.
Gavi defines “co-financing” as contributions made by national governments to cover part of the cost of Gavi-funded vaccines. Countries effectively co-procure a portion of their new vaccines and safe injection devises requirements. Co-financing of vaccines is one of the ways in which Gavi countries support immunisation, complementing national investments in health and immunisation systems and programmes. The objective of the co-financing policy is putting countries on a trajectory towards financial sustainability in order to prepare them for phasing out of Gavi support for new vaccines.
The timeframe for attaining financial sustainability will vary across countries. For the poorest countries, many years may be required to achieve financial sustainability, and therefore an intermediate objective is to gradually enhance country contribution and ownership of vaccine financing.
The vaccines exempt from co-financing are measles second dose, inactivated polio vaccine (IPV), Japanese Encephalitis, HPV demonstration programmes, and campaigns with measles-rubella, meningococcal A and yellow fever vaccines.